<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01339143</url>
  </required_header>
  <id_info>
    <org_study_id>AN10016-002</org_study_id>
    <nct_id>NCT01339143</nct_id>
  </id_info>
  <brief_title>Compare the Effect of DPP-IV Inhibitor or TZD on Glycemic Variability and Oxidative Stress in Patient With 2 Diabetes</brief_title>
  <official_title>An Open-label, Randomized, Active-controlled Study to Compare the Effect of DPP-IV Inhibitor and TZD as add-on Therapy to Metformin on Glycemic Variability and Oxidative Stress in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University Anam Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea University Anam Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effect of vildagliptin vs. pioglitazone to
      oxidative stress on daily blood glucose fluctuations, in patients with type 2 diabetes that
      was inadequately controlled by metformin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Activation of oxidative stress by glucose fluctuations plays a major role in the pathogenesis
      of diabetic complication. Dipeptidyl peptidase IV (DPP-IV), such as vildagliptin, enhances
      glucose-induced insulin secretion, decreases glucagon secretion, and reduces postprandial
      hyperglycemia and may also improve acute fluctuations of glucose. We believe that
      vildagliptin may exert an effect of decreasing oxidative stress by reducing glucose
      excursion.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">May 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycemic Variability</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxidative stress</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1C</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hypoglycemia</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Oxidative Stress</condition>
  <arm_group>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pioglitazone: 15mg, QD, PO, 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vildagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vildagliptin 50mg,BID,PO,16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Galvus (vildagliptin)</intervention_name>
    <description>50mg BID, PO, for 16 weeks</description>
    <arm_group_label>vildagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pioglitazone</intervention_name>
    <description>15mg, QD, PO, 16 weeks</description>
    <arm_group_label>Pioglitazone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female with age 18-80 years

          -  Type 2 diabetes mellitus

          -  On stable dose of metformin (more than 1000mg) for at least 1 month

          -  HbA1c 7~10%

          -  Subjects on statins, ACE inhibitors, ARBs and antioxidants will be allowed as long as
             they are on stable doses of these compounds and the dosage is not changed during the
             course of study

          -  BP under control - no change required to BP medications

          -  Agreement to maintain prior diet &amp; exercise

        Exclusion Criteria:

          -  Type 1 DM or Any kind of secondary DM

          -  Pregnant or lactating women.

          -  Treatment with sulfonylurea, Î±-glucosidase inhibitor, glinide, GLP-1 analogues, DPP-IV
             inhibitors or insulin therapy within 1 month prior to informed consent.

          -  Treatment with rosiglitazone or pioglitazone within 3 months prior to informed
             consent.

          -  HbA1c &lt;7% or &gt;10%

          -  Uncontrolled hypertension ( BP &gt; 160/100 mmHg)

          -  Congestive heart failure (NYHA class I to IV).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sin-Gon Kim, Dr., Ph.D.</last_name>
    <phone>82-2-920-5830</phone>
    <email>k50367@korea.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Juri Park, Dr.,Ph.D</last_name>
    <phone>82-2-2224-2590</phone>
    <email>poirio@naver.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2011</study_first_submitted>
  <study_first_submitted_qc>April 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2011</study_first_posted>
  <last_update_submitted>May 5, 2011</last_update_submitted>
  <last_update_submitted_qc>May 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2011</last_update_posted>
  <responsible_party>
    <name_title>Sin-Gon Kim</name_title>
    <organization>Korea University Anam Hospital</organization>
  </responsible_party>
  <keyword>Vildagliptin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Vildagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

